iGlarLixi versus basal plus Rapid‐Acting insulin in adults with type 2 diabetes advancing from basal insulin therapy: The SoliSimplify Real‐World study

Abstract Aim For people with suboptimally controlled type 2 diabetes (T2D) on basal insulin (BI), guidelines recommend several treatment advancement options. This study compared the clinical effectiveness of once‐daily iGlarLixi versus a multiple‐injection BI + rapid acting insulin (RAI) regimen in adults with T2D advancing from BI therapy in real‐world clinical practice. Materials and methods Electronic medical records from the Observational Medical Outcomes Partnership (OMOP) database were analysed retrospectively using propensity score matching to compare therapy advancement with iGlarLixi or BI + RAI in US adults ≥18 years with T2D on BI who had ≥1 valid glycated haemoglobin (HbA1c) value at baseline and at the 6‐month follow‐up. The primary objective was non‐inferiority of iGlarLixi to BI + RAI in HbA1c change from baseline to 6 months (margin 0.3%). Results Propensity score matching generated cohorts with balanced baseline characteristics (N = 814 in each group). HbA1c reduction from baseline to 6 months with iGlarLixi was non‐inferior to BI + RAI [mean difference (95% confidence interval): 0.1 (−0.1, 0.2)%; one‐sided p = .0032]. At 6 months, weight gain was significantly lower with iGlarLixi than with BI + RAI [−0.8 (−1.3, −0.2) kg; two‐sided p = .0069]. Achievement of HbA1c <7% without hypoglycaemia and weight gain were similar between groups [odds ratio (95% confidence interval): 1.15 (0.81, 1.63); p = .4280]. Hypoglycaemia was low in both groups, probably because of underreporting. Conclusions In real‐world clinical practice, glycaemic outcomes 6 months after treatment advancement from BI are similar for people with T2D using iGlarLixi versus BI + RAI, with iGlarLixi leading to less weight gain.